3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
3
Phase 3
1
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Pain
5
Neoplasms
5
Pain, Intractable
3
Agnosia
3
Pain, Postoperative
2
Waldenstrom Macroglobulinemia
1
Thrombocythemia, Essential
1
Spinal Stenosis
1
Sezary Syndrome
1
Primary Myelofibrosis
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Peripheral Nervous System Diseases
1
Pdgfra-Associated Chronic Eosinophilic Leukemia
1
Pain, Procedural
1
Neurotoxicity Syndromes
1
Myeloproliferative Disorders
1
Mycosis Fungoides
1
Multiple Myeloma
1
Mucositis
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, Extranodal NK-T-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Interventions
Sodium Chloride
2
6'-fluoro-4',9'-dihydro-N,N-dimethyl-4-phenylspiro(cyclohexane-1,1'(3'H)-pyrano(3,4-b)indol)-4-amine
2
Tapentadol
1
Ropivacaine
1
Pregabalin
1
Meloxicam
1
Lidocaine
1
Ketorolac Tromethamine
1
Ketorolac
1
Ketamine
1
Fentanyl
1
Educational Status
1
Anti-Inflammatory Agents, Non-Steroidal
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Chronic Pain
×
Ketamine
×
Clear all
NCT02303847
2015-05-27
Ketamine
University of Washington
Phase 3
Unknown
32 enrolled